Dravet Syndrome Market


DelveInsight’s ‘Dravet Syndrome Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Dravet Syndrome (DS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The Dravet Syndrome market report provides analysis regarding current treatment practices, emerging drug-like Cannabidiol, potential therapies, market share of the individual therapies, historical, current and forecasted Dravet Syndrome market size from 2017 to 2030 segmented by seven major markets.


The report also covers current Dravet Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.


Geography Covered

  • The United States
  •  EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  •  Japan


Study Period: 2017–2030


Dravet Syndrome - Disease Understanding and Treatment Algorithm

Dravet Syndrome Overview

Dravet Syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.


It occupies a very distinct place among rare and severe epilepsies, which is quite evident from the names it was given during its short and eventful history. Initially “Severe myoclonic epilepsy of infancy” (SMEI) was distinguished from Lennox–Gastaut syndrome (LGS) which was then considered as the most common severe epilepsy of childhood, and with which it shared pharmacoresistance, episodes of status epilepticus (SE) and intellectual disability.


Dravet Syndrome Treatment

This chapter covers the details of conventional and current medical therapies available in the Dravet Syndrome market for the treatment of the condition. It also provides the country-wise Dravet Syndrome treatment guidelines across the United States, Europe and Japan.


DelveInsight’s Dravet Syndrome market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Dravet Syndrome treatment algorithms and treatment guidelines in the US, Europe, and Japan.


Dravet Syndrome Epidemiology

The Dravet Syndrome epidemiology chapters provide insights about historical and current Dravet Syndrome patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Incidence of Dravet Syndrome segments Dravet Syndrome epidemiology, Mutation positive cases, Mutation Cases by Types and Class, Seizures associated with Dravet Syndrome, Gender-specific cases and Age-specific cases of Dravet Syndrome. The report includes thorough analysis of all segmentations.


Mutation Positive Cases in Dravet Syndrome can be divided into two subtypes: by types (SCN1A mutation associated with DS and other rare mutations associated with DS) and by class (Missense, Nonsense, Frameshift, Splice site, Inframe Insertion/Deletion and Gross Rearrangements). In the US, the cases of mis-sence mutation in Dravet Syndrome were found to be 6,734 in 2017. Moreover, the cases of SCN1A mutation associated with DS were reported to be 13,175 in the country.


According to DelveInsight’s, the total incident population of Dravet Syndrome in seven major markets was 30,820 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).


Among all the seven major markets, the United States accounts for the highest number of Dravet Syndrome cases.


Dravet Syndrome Drug Chapters

Drug chapter segment of the Dravet Syndrome report encloses the detailed analysis of Dravet Syndrome pipeline drug. It also helps to understand the Dravet Syndrome clinical trial details, expressive pharmacological action, agreements of included drug and the latest news and press releases.


The primary aim in managing patients with DS is to significantly reduce seizure frequency (particularly prolonged events) and limit antiepileptic drug toxicity First-line management typically involves either valproic acid or clobazam. Zogenix’s ZX008, Ovid/Takeda’s Soticlestat and PTC Therapeutics’s Ataluren are the only therapies in pipeline.


Dravet Syndrome Market Outlook

The Dravet Syndrome market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the highest Dravet Syndrome market size. Among EU5 countries, the United Kingdom had the highest market size with USD 3.9 million in 2017, while Spain had the lowest market size of DS with USD 1.9 million in 2017.


Dravet Syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Dravet Syndrome market or expected to get launched in the market during the study period 2017-2030. The analysis covers Dravet Syndrome market uptake by drugs; patient uptake by therapies; and sale of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


The dynamics of DS market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.


Dravet Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Dravet Syndrome key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of Dravet Syndrome collaborations, acquisition and merger, licensing, patent details and other information for Dravet Syndrome emerging therapies.


Reimbursement Scenario in Dravet Syndrome

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.


KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Dravet Syndrome domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.


Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Dravet Syndrome Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.


Report Highlights

  • In the coming years, Dravet Syndrome market scenario is expected to alter across the 7MM due shift of focus from symptomatic treatment and maturation of the pipeline to include disease-modifying treatment.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Dravet Syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Dravet Syndrome Pipeline Analysis
  • Dravet Syndrome Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Dravet Syndrome Report Key Strengths

  • 11 years Forecast
  • 7MM Coverage
  • Dravet Syndrome Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Dravet Syndrome Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Dravet Syndrome market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Dravet Syndrome total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Dravet Syndrome market size during the forecast period (2017–2030)?
  • At what CAGR, the Dravet Syndrome market is expected to grow in 7MM during the forecast period (2017–2030)?
  • What would be the Dravet Syndrome market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Dravet Syndrome market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Dravet Syndrome?
  • What is the historical Dravet Syndrome patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Dravet Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dravet Syndrome?
  • Out of all 7MM countries, which country would have the highest incidence population of Dravet Syndrome during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Dravet Syndrome treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Dravet Syndrome in the USA, Europe, and Japan?
  • What are the Dravet Syndrome marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Dravet Syndrome?
  • How many therapies are developed by each company for Dravet Syndrome treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Dravet Syndrome treatment?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dravet Syndrome therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Dravet Syndrome and their status?
  • What are the key designations that have been granted for the emerging therapies for Dravet Syndrome?
  • What are the global historical and forecasted market of Dravet Syndrome?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Dravet Syndrome market
  • To understand the future market competition in the Dravet Syndrome market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome market
  • To understand the future market competition in the Dravet Syndrome market


Which geography accounted for the largest Dravet Syndrome market size?

United States accounted for the largest Dravet Syndrome market size.


What is forecasted Dravet Syndrome market size in 2030?

DelveInsight estimates an increase in DS Market Size during the study period, 2017–2030.


What are the present Dravet Syndrome market drivers?

Increasing research and developmental activities in order to find novel targets and improving current challenges along with increasing awareness among the people.


What are the Dravet Syndrome market barriers?

Paucity of data regarding effective strategies, comparatively reduced focus along with diagnostic challenges.


How many companies are developing drugs for Dravet Syndrome?

Currently three key pharma players are developing drug for Dravet Syndrome.


Which are the leading companies in Dravet Syndrome market?

Key Players – Ovid Therapeutics/Takeda, PTC Therapeutics and Zogenix.


How is epidemiology segmented for Dravet Syndrome?

Incidence of Dravet Syndrome, Mutation positive cases of Dravet Syndrome, Mutational cases associated with DS by Types and Class, Seizures associated cases with DS, Gender-specific cases and Age-specific cases of Dravet Syndrome.

1 Key Insights

2 Executive Summary of Dravet Syndrome

3 SWOT Analysis for Dravet Syndrome

4 Dravet Syndrome Market Overview at a Glance

4.1 Market Share (%) Distribution of Dravet Syndrome in 2017

4.2 Market Share (%) Distribution of Dravet Syndrome in 2030

5 Dravet Syndrome: Disease Background and Overview

5.1 Introduction

5.2 Clinical Features of Dravet Syndrome

5.2.1 Epilepsy

5.2.2 Cognition

5.2.3 Movement disorders

5.2.4 Sudden Death

5.3 Genetics of Dravet Syndrome

5.3.1 Sodium Channel a1 Subunit Gene (SCN1A) and its association with Dravet Syndrome

5.3.2 Functional aspects of voltage gate sodium channel mutations

5.3.3 Detection of SCN1A mutations

5.3.4 Inheritance mode and pattern

5.3.5 Dravet Syndrome without SCN1A Alterations

5.4 Signs and Symptoms of Dravet Syndrome

5.5 Pathophysiology

5.6 Diagnosis of Dravet Syndrome

5.6.1 Differential diagnosis

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Total Incidence of Dravet Syndrome in 7MM

7 Country Wise-Epidemiology of Dravet Syndrome

8 United States

8.1 Assumptions and Rationale

8.2 Incident Population of Dravet Syndrome

8.3 Mutations associated with Dravet Syndrome

8.3.1 Incidence of Dravet Syndrome by Mutation Class

8.3.2 Incidence of Dravet Syndrome by Mutation Type

8.4 Seizure associated cases of Dravet Syndrome

8.5 Gender-specific Incidence of Dravet Syndrome

8.6 Age-specific Incidence of Dravet Syndrome

9 EU-5

9.1 Assumptions and Rationale

10 Germany

10.1 Incident Population of Dravet Syndrome

10.2 Mutations associated with Dravet Syndrome

10.2.1 Incidence of Dravet Syndrome by Mutation Class

10.2.2 Incidence of Dravet Syndrome by Mutation Type

10.3 Seizure associated cases of Dravet Syndrome

10.4 Gender-specific Incidence of Dravet Syndrome

10.5 Age-specific Incidence of Dravet Syndrome

11 France

11.1 Incident Population of Dravet Syndrome

11.2 Mutations associated with Dravet Syndrome

11.2.1 Incidence of Dravet Syndrome by Mutation Class

11.2.2 Incidence of Dravet Syndrome by Mutation Type

11.3 Seizure associated cases of Dravet Syndrome

11.4 Gender-specific Incidence of Dravet Syndrome

11.5 Age-specific Incidence of Dravet Syndrome

12 Italy

12.1 Incident Population of Dravet Syndrome

12.2 Mutations associated with Dravet Syndrome

12.2.1 Incidence of Dravet Syndrome by Mutation Class

12.2.2 Incidence of Dravet Syndrome by Mutation Type

12.3 Seizure associated cases of Dravet Syndrome

12.4 Gender-specific Incidence of Dravet Syndrome

12.5 Age-specific Incidence of Dravet Syndrome

13 Spain

13.1 Incident Population of Dravet Syndrome

13.2 Mutations associated with Dravet Syndrome

13.2.1 Incidence of Dravet Syndrome by Mutation Class

13.2.2 Incidence of Dravet Syndrome by Mutation Type.

13.3 Seizure associated cases of Dravet Syndrome

13.4 Gender-specific Incidence of Dravet Syndrome

13.5 Age-specific Incidence of Dravet Syndrome

14 United Kingdom

14.1 Incident Population of Dravet Syndrome

14.2 Mutations associated with Dravet Syndrome

14.2.1 Incidence of Dravet Syndrome by Mutation Class

14.2.2 Incidence of Dravet Syndrome by Mutation Type

14.3 Seizure associated cases of Dravet Syndrome

14.4 Gender-specific Incidence of Dravet Syndrome

14.5 Age-specific Incidence of Dravet Syndrome

15 Japan

15.1 Assumptions and Rationale

15.2 Incident Population of Dravet Syndrome

15.3 Mutations associated with Dravet Syndrome

15.3.1 Incidence of Dravet Syndrome by Mutation Class

15.3.2 Incidence of Dravet Syndrome by Mutation Type

15.4 Seizure associated cases of Dravet Syndrome

15.5 Gender-specific Incidence of Dravet Syndrome

15.6 Age-specific Incidence of Dravet Syndrome

16 Treatment of Dravet Syndrome

16.1 Current Treatment Practices

16.1.1 First-Line Therapies: Valproic Acid and Clobazam

16.1.2 Second-Line Therapies

16.1.3 Third Line of Therapies

16.2 Treatment Algorithm

17 Unmet Needs

18 Organizations contributing toward Dravet Syndrome

19 KOL’s Views: Dravet Syndrome

20 Case Studies

20.1 Anesthetic Management of Dravet Syndrome

20.2 Dravet Syndrome and Parkinsonism

21 Marketed Drugs

21.1 Diacomit: Biocodex

21.1.1 Drug Description

21.1.2 Mechanism of Action

21.1.3 Regulatory Milestones

21.1.4 Advantages and Disadvantages

21.1.5 Safety and Efficacy

21.2 Epidiolex: GW Pharmaceuticals

21.2.1 Drug Description

21.2.2 Mechanism of Action

21.2.3 Regulatory Milestones

21.2.4 Advantages and Disadvantages

21.2.5 Safety and Efficacy

22 Emerging Therapies

22.1 ZX-008: Zogenix

22.1.1 Product Description

22.1.2 Other Development Activities

22.1.3 Clinical Development

22.1.4 Safety and Efficacy

22.1 Soticlestat: Ovid Therapeutics

22.1.1 Product Description

22.1.2 Other Development Activities

22.1.3 Clinical Development

22.1.4 Safety and Efficacy

22.2 Ataluren: PTC Therapeutics

22.2.1 Product Description

22.2.2 Clinical Development

23 Dravet Syndrome: Seven Major Market Analysis

23.1 Key Findings

23.2 Total Market Size of Dravet Syndrome in 7MM

24 Market Outlook by Country

24.1 The United States: Market Outlook

24.2 United States Market Size

24.2.1 Total Market Size of Dravet Syndrome

24.2.2 Dravet Syndrome Market Size by Therapies

24.3 EU-5 Countries: Market Outlook

24.4 Germany Market Size

24.4.1 Total Market Size of Dravet Syndrome

24.4.2 Dravet Syndrome Market Size by Therapies

24.5 France Market Size

24.5.1 Total Market Size of Dravet Syndrome

24.5.2 Dravet Syndrome Market Size by Therapies

24.6 Italy Market Size

24.6.1 Total Market Size of Dravet Syndrome

24.6.2 Dravet Syndrome Market Size by Therapies

24.7 Spain Market Size

24.7.1 Total Market Size of Dravet Syndrome

24.7.2 Dravet Syndrome Market Size by Therapies

24.8 The United Kingdom Market Size

24.8.1 Total Market Size of Dravet Syndrome

24.8.2 Dravet Syndrome Market Size by Therapies

24.9 Japan: Market Outlook

24.10 Japan: Market Size

24.10.1 Total Market Size of Dravet Syndrome

24.10.2 Dravet Syndrome Market Size by Therapies

25 Market Drivers

26 Market Barriers

27 Appendix

28 Report Methodology

28.1 Sources Used

29 DelveInsight Capabilities

30 Disclaimer

31 About DelveInsight

List of Table

Table 1: Genetic background of Dravet syndrome

Table 2: Total Incident Population of Dravet Syndrome in 7MM (2017–2030)

Table 3: Incident Population of Dravet Syndrome in the United States (2017–2030)

Table 4: Mutation positive cases of Dravet Syndrome in the United States (2017–2030)

Table 5: Incidence of Dravet Syndrome by Mutation Class in the United States (2017–2030)

Table 6: Incidence of Dravet Syndrome by Mutation Type in the United States (2017–2030)

Table 7: Seizure associated cases of Dravet Syndrome in the United States (2017–2030)

Table 8: Gender-specific Incidence of Dravet Syndrome in the United States (2017–2030)

Table 9: Age-specific Incidence of Dravet Syndrome in the United States (2017–2030)

Table 10: Incident Population of Dravet Syndrome in Germany (2017–2030)

Table 11: Mutation positive cases of Dravet Syndrome in Germany (2017–2030)

Table 12: Incidence of Dravet Syndrome by Mutation Class in Germany (2017–2030)

Table 13: Incidence of Dravet Syndrome by Mutation Type in Germany (2017–2030)

Table 14: Seizure associated cases of Dravet Syndrome in Germany (2017–2030)

Table 15: Gender-specific Incidence of Dravet Syndrome in Germany (2017–2030)

Table 16: Age-specific Incidence of Dravet Syndrome in Germany (2017–2030)

Table 17: Incident Population of Dravet Syndrome in France (2017–2030)

Table 18: Mutation positive cases of Dravet Syndrome in France (2017–2030)

Table 19: Incidence of Dravet Syndrome by Mutation Class in France (2017–2030)

Table 20: Incidence of Dravet Syndrome by Mutation Type in France (2017–2030)

Table 21: Seizure associated cases of Dravet Syndrome in France (2017–2030)

Table 22: Gender-specific Incidence of Dravet Syndrome in France (2017–2030)

Table 23: Age-specific Incidence of Dravet Syndrome in France (2017–2030)

Table 24: Incident Population of Dravet Syndrome in Italy (2017–2030)

Table 25: Mutation positive cases of Dravet Syndrome in Italy (2017–2030)

Table 26: Incidence of Dravet Syndrome by Mutation Class in Italy (2017–2030)

Table 27: Incidence of Dravet Syndrome by Mutation Type in Italy (2017–2030)

Table 28: Seizure associated cases of Dravet Syndrome in Italy (2017–2030)

Table 29: Gender-specific Incidence of Dravet Syndrome in Italy (2017–2030)

Table 30: Age-specific Incidence of Dravet Syndrome in Italy (2017–2030)

Table 31: Incident Population of Dravet Syndrome in Spain (2017–2030)

Table 32: Mutation positive cases of Dravet Syndrome in Spain (2017–2030)

Table 33: Incidence of Dravet Syndrome by Mutation Class in Spain (2017–2030)

Table 34: Incidence of Dravet Syndrome by Mutation Type in Spain (2017–2030)

Table 35: Seizure associated cases of Dravet Syndrome in Spain (2017–2030)

Table 36: Gender-specific Incidence of Dravet Syndrome in Spain (2017–2030)

Table 37: Age-specific Incidence of Dravet Syndrome in Spain (2017–2030)

Table 38: Incident Population of Dravet Syndrome in the United Kingdom (2017–2030)

Table 39: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017–2030)

Table 40: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017–2030)

Table 41: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017–2030)

Table 42: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017–2030)

Table 43: Gender-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)

Table 44: Age-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)

Table 45: Incident Population of Dravet Syndrome in Japan (2017–2030)

Table 46: Mutation positive cases of Dravet Syndrome in Japan (2017–2030)

Table 47: Incidence of Dravet Syndrome by Mutation Class in Japan (2017–2030)

Table 48: Incidence of Dravet Syndrome by Mutation Type in Japan (2017–2030)

Table 49: Seizure associated cases of Dravet Syndrome in Japan (2017–2030)

Table 50: Gender-specific Incidence of Dravet Syndrome in Japan (2017–2030)

Table 51: Age-specific Incidence of Dravet Syndrome in Japan (2017–2030)

Table 52: Organizations contributing towards Dravet Syndrome

Table 53: Seven Major Market Size of Dravet Syndrome in USD Million (2017–2030)

Table 54: 7MM Size of Dravet Syndrome by Therapies in USD Million (2017–2030)

Table 55: The US Market Dravet Syndrome in USD Million (2017–2030)

Table 56: The US Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Table 57: Germany Market of Dravet Syndrome in USD Million (2017–2030)

Table 58: Germany Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Table 59: France Market of Dravet Syndrome in USD Million (2017–2030)

Table 60: France Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Table 61: Italy Market of Dravet Syndrome in USD Million (2017–2030)

Table 62: Italy Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Table 63: Spain Market of Dravet Syndrome in USD Million (2017–2030)

Table 64: Spain Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Table 65: UK Market of Dravet Syndrome in USD Million (2017–2030)

Table 66: UK Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Table 67: Japan Market of Dravet Syndrome in USD Million (2017–2030)

List of Figures

Figure 1: Schematic representation of clinical manifestations of Dravet syndrome

Figure 2: Differential diagnosis of Dravet syndrome in the course of the disease

Figure 3: Total Incident Population of Dravet Syndrome in 7 MM (2017–2030)

Figure 4: Incident Population of Dravet Syndrome in the United States (2017–2030)

Figure 5: Mutation positive cases of Dravet Syndrome in the United States (2017–2030)

Figure 6: Incidence of Dravet Syndrome by Mutation Class in the United States (2017–2030)

Figure 7: Incidence of Dravet Syndrome by Mutation Type in the United States (2017–2030)

Figure 8: Seizure associated cases of Dravet Syndrome in the United States (2017–2030)

Figure 9: Gender-specific Incidence of Dravet Syndrome in the United States (2017–2030)

Figure 10: Age-specific Incidence of Dravet Syndrome in the United States (2017–2030)

Figure 11: Incident Population of Dravet Syndrome in Germany (2017–2030)

Figure 12: Mutation positive cases of Dravet Syndrome in Germany (2017–2030)

Figure 13: Incidence of Dravet Syndrome by Mutation Class in Germany (2017–2030)

Figure 14: Incidence of Dravet Syndrome by Mutation Type in Germany (2017–2030)

Figure 15: Seizure associated cases of Dravet Syndrome in Germany (2017–2030)

Figure 16: Gender-specific Incidence of Dravet Syndrome in Germany (2017–2030)

Figure 17: Age-specific Incidence of Dravet Syndrome in Germany 2017–2030)

Figure 18: Incident Population of Dravet Syndrome in France (2017–2030)

Figure 19: Mutation positive cases of Dravet Syndrome in France (2017–2030)

Figure 20: Incidence of Dravet Syndrome by Mutation Class in France (2017–2030)

Figure 21: Incidence of Dravet Syndrome by Mutation Type in France (2017–2030)

Figure 22: Seizure associated cases of Dravet Syndrome in France (2017–2030)

Figure 23: Gender-specific Incidence of Dravet Syndrome in France (2017–2030)

Figure 24: Age-specific Incidence of Dravet Syndrome in France (2017–2030)

Figure 25: Incident Population of Dravet Syndrome in Italy (2017–2030)

Figure 26: Mutation positive cases of Dravet Syndrome in Italy (2017–2030)

Figure 27: Incidence of Dravet Syndrome by Mutation Class in Italy (2017–2030)

Figure 28: Incidence of Dravet Syndrome by Mutation Type in Italy (2017–2030)

Figure 29: Seizure associated cases of Dravet Syndrome in Italy (2017–2030)

Figure 30: Gender-specific Incidence of Dravet Syndrome in Italy (2017–2030)

Figure 31: Age-specific Incidence of Dravet Syndrome in Italy (2017–2030)

Figure 32: Incident Population of Dravet Syndrome in Spain (2017–2030)

Figure 33: Mutation positive cases of Dravet Syndrome in Spain (2017–2030)

Figure 34: Incidence of Dravet Syndrome by Mutation Class in Spain (2017–2030)

Figure 35: Incidence of Dravet Syndrome by Mutation Type in Spain (2017–2030)

Figure 36: Seizure associated cases of Dravet Syndrome in Spain (2017–2030)

Figure 37: Gender-specific Incidence of Dravet Syndrome in Spain (2017–2030)

Figure 38: Age-specific Incidence of Dravet Syndrome in Spain (2017–2030)

Figure 39: Incident Population of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 40: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 41: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017–2030)

Figure 42: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017–2030)

Figure 43: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 44: Gender-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 45: Age-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 46: Incident Population of Dravet Syndrome in Japan (2017–2030)

Figure 47: Mutation positive cases of Dravet Syndrome in Japan (2017–2030)

Figure 48: Incidence of Dravet Syndrome by Mutation Class in Japan (2017–2030)

Figure 49: Incidence of Dravet Syndrome by Mutation Type in Japan (2017–2030)

Figure 50: Seizure associated cases of Dravet Syndrome in Japan (2017–2030)

Figure 51: Gender-specific Incidence of Dravet Syndrome in Japan (2017–2030)

Figure 52: Age-specific Incidence of Dravet Syndrome in Japan (2017–2030)

Figure 53: Treatment algorithm of epilepsy in Dravet syndrome.

Figure 54: Unmet Needs for Dravet Syndrome

Figure 55: Seven Major Market Size of Dravet Syndrome in USD Million (2017–2030)

Figure 56: Market Size of Dravet Syndrome in the United States, USD Millions (2017–2030)

Figure 57: The US Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Figure 58: Market Size of Dravet Syndrome in Germany, USD Millions (2017–2030)

Figure 59: Germany Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Figure 60: Market Size of Dravet Syndrome in France, USD Millions (2017–2030)

Figure 61: France Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Figure 62: Market Size of Dravet Syndrome in Italy, USD Millions (2017–2030)

Figure 63: Italy Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Figure 64: Market Size of Dravet Syndrome in Spain, USD Millions (2017–2030)

Figure 65: Spain Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Figure 66: Market Size of Dravet Syndrome in the UK, USD Millions (2017–2030)

Figure 67: The UK Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Figure 68: Market Size of Dravet Syndrome in Japan, USD Millions (2017–2030)

Figure 69: Japan Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)

Figure 70: Market Drivers of Dravet Syndrome

Figure 71: Market Barriers of Dravet Syndrome

Dravet Syndrome market,

Dravet Syndrome market research,

Dravet Syndrome Companies,

Dravet Syndrome market trends,

Dravet Syndrome market forecast,

Dravet Syndrome market share,

Dravet Syndrome pipeline,

Dravet Syndrome treatment algorithm,

Dravet Syndrome drugs,

Dravet Syndrome sales forecasting,

Dravet Syndrome market size,

Dravet Syndrome disease,

Dravet Syndrome epidemiology,Dravet Syndrome

  • Tags:
  • Dravet Syndrome market
  • Dravet Syndrome market research
  • Dravet Syndrome market insight
  • Dravet Syndrome market trends
  • Dravet Syndrome market forecast
  • Dravet Syndrome market share
  • Dravet Syndrome pipeline drugs
  • Dravet Syndrome treatment algorithm
  • Dravet Syndrome drugs
  • Dravet Syndrome sales forecasting
  • Dravet Syndrome market size
  • Dravet Syndrome disease
  • Dravet Syndrome epidemiology
  • Dravet Syndrome

Forward to Friend

Need A Quote